Targeted liver attack: new combo therapy tested for tough cancers
NCT ID NCT05220722
Summary
This early-stage study tested a new drug called SD-101, delivered directly into the liver's main artery, for people with advanced liver cancer. It aimed to see if combining this local treatment with standard immunotherapy drugs was safe and could help control the cancer. The trial was small and ended early, so its results are preliminary.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.